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To determine if sequence variations observed in cosmopolitan HTLV-I interfered with viral recognition by neutralizing
antibodies, we evaluated the neutralization potential of sera from persons infected by HTLV-I of this clade selected for amino
acid changes in their env glycoproteins. Each serum was used to neutralize three previously described HTLV-I isolates, 2060,
2072, and 1010, that possess amino acid env sequences differing at several positions, one of them being located in the
immunodominant and neutralizable domain (aa 187–199). The results obtained in syncytia and/or reporter gene inhibition
assays showed that the neutralization pattern of the sera clearly differed and could be classified in three categories. Five
sera completely neutralized the three viruses with an equivalent titer, two sera gave a maximum inhibition, with higher ID50
on the 2072 virus than on the 2060 or 1010 viruses, and three sera had a stronger neutralization potential toward the 1010
virus than toward the 2060 virus. One of these sera partially neutralized the virus produced by 2072 cells, whereas
neutralizing antibodies in the other two recognized the neutralizable epitopes on the 1010 or 2072 viruses equally well.
Identification of amino acid sequences involved in induction of neutralizing antibodies with different recognition capacities
could help identify new neutralizable epitopes of HTLV-I envelope glycoproteins and to better define the component(s) of an
effective vaccine. © 1998 Academic Press
INTRODUCTION
Human T cell leukemia virus type I is the etiological
agent of an adult T cell leukemia (ATL) and a chronic
neurological disease (TSP/HAM) (Poiesz et al., 1980;
Hinuma et al., 1981; Yoshida et al., 1982; Gessain et al.,
1985; Osame et al., 1986). A striking feature of HTLV-I is
that only 1–5% of infected persons develop one of these
severe diseases, generally after a long latency. During
this long period as well as during disease progression,
there is little expression of virus, although antibodies
against HTLV-I proteins are detectable and even in-
crease in TSP/HAM patients (Kalyanaraman et al., 1981;
Robert-Guroff et al., 1982; Hinuma et al., 1982). Some of
these antibodies from infected persons have been
shown to neutralize the virus in syncytium and reporter
gene inhibition assays (Nagy et al., 1983; Astier-Gin et al.,
1997) as well as in vesicular stomatitis virus–HTLV
pseudotype neutralization tests (Clapham et al., 1984;
Hoshino et al., 1985). Several neutralizable epitopes have
now been mapped on the surface envelope glycoprotein
gp46 (reviewed in Hart et al., 1995), the major ones being
located in a region between amino acids 187 and 199.
Rodents injected with peptides encompassing gp46 neu-
tralizable epitopes develop a humoral immune response
that prevents HTLV-I infection both in vivo (Dezzutti et al.,
1990) and in vitro (Tanaka et al., 1991). In humans, there
is a correlation between the amount of antibodies di-
rected against this gp46 domain in sera from HTLV-I-
positive patients and HTLV-I neutralizing activity (Astier-
Gin et al., 1997). The majority of the neutralizable
epitopes displayed on the HTLV-I envelope glycoprotein
appear to be type-specific, because they elicit antibodies
that do not neutralize HTLV-II, although limited cross-
neutralizing activity between HTLV-I and HTLV-II has
been detected in some patient sera (Clapham et al.,
1984; Palker et al., 1992; Astier-Gin et al., 1995).
The HTLV-I sequence is highly conserved. The
HTLV-Is from Japan, Africa, the West Indies, and the
Americas belonging to the cosmopolitan clade exhibit at
least 97% sequence similarity at the nucleotide level.
Using vesicular stomatitis virus (VSV) pseudotypes bear-
ing envelope antigens of Japanese and American strains
of HTLV-I, it has been established that sera from the
United States, the Caribbean basin, and Japan com-
pletely neutralize viral infectivity, indicating that the
HTLV-I isolates from these distinct geographic regions
represent a single envelope serotype (Clapham et al.,
1984; Hoshino et al., 1985). These observations suggest
that genetically engineered HTLV-I envelope (env) pro-
teins or synthetic peptide-based subunits could be em-
ployed in a vaccine against HTLV-I. Such a vaccine
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would be valuable in developing countries where other
preventive methods are not practicable (especially
avoidance of breast feeding).
The protective humoral and cellular immune re-
sponses elicited by vaccine components could, however,
be eluded by HTLV-I viruses bearing antigenically differ-
ent proteins. More distant strains (Melanesian clade)
displaying 8% variation in nucleotide sequences have
been found in remote populations from the Solomon
Islands, Papua New Guinea, and Australia (Gessain et
al., 1991). Two independent reports have identified cross-
neutralizing antibodies against cosmopolitan and
Melanesian strains of HTLV-I in sera from inhabitants of
Japan, Africa, and Melanesia (Hoshino et al., 1993; Ben-
son et al., 1994). However, such cross-neutralization is
not complete with some sera (Benson et al., 1994) and
higher neutralizing antibody titers have been found to-
ward strains in the same clade than to those in the other
clade. Even in the cosmopolitan group of HTLV-I, where
the nucleotide sequence is highly conserved, some
amino acid changes (A1873 T and P1923 S) located in
the env protein sequences (the most likely target of
neutralizing antibodies) have been shown to affect the
binding of monoclonal (Schulz et al., 1991) and human
antibodies (Edouard et al., 1994). Such variations could
well affect the antigenicity of neutralizable epitopes
To address this question, we used syncytium and
reporter gene inhibition assays to evaluate the cross-
neutralizing activity of sera from persons infected with
cosmopolitan HTLV-Is harboring several amino acid
changes in their env glycoproteins, one of which was
located in the immunodominant and neutralizable do-
main (aa 187–199).
RESULTS
Sample selection
Previous seroneutralization experiments performed on
Japanese and American strains of HTLV-I indicated that
the HTLV-I isolates from these distinct geographic areas
represented a single serotype. These analyses were
carried out on sera of patients infected with viruses
whose env protein amino acid sequences were un-
known. As the HTLV-I sequence is highly conserved,
sequence variations found in a minority of viral strains
but affecting the antigenicity of the surface envelope
gp46 might not have been present in the previously
studied samples. Our laboratory possesses a large se-
ries of blood samples obtained from HTLV-I-infected pa-
tients originating from French Guiana, the West Indies,
and Africa. In most cases, we had in hand for the same
patient the sera used for the immunological analyses
and the DNA from peripheral blood lymphocytes used for
sequence determination of the env gene. Figure 1 shows
the alignment of the deduced amino acid sequences of
the leader peptide and of the gp46 surface envelope
glycoprotein of 11 newly sequenced HTLV-I proviruses
selected for substitutions at different positions. In two
cases, 2060 and 2072, the deduced amino acid se-
quences of the gp21 transmembrane glycoprotein are
also presented.
For comparison, 6 well-documented env sequences
are included. Consistent with the results obtained by
several groups, few variations were observed among
these gp46 sequences. Among 17 different sequences,
we only observed 21 substitutions (aa 19 is located in the
leader sequence) in the 287 amino acids of gp46. Env
sequences could be arranged in three groups, each
displaying the same residues in the major immunodom-
inant and neutralizable domain (aa 187–199). Neverthe-
less, within each group, different aa could be substituted
at other positions, some of them belonging to another
neutralizable region recognized by a minority of HTLV-I-
positive human sera (aa 86–107). It is thus conceivable
that antigenically different HTLV-I exist, even in this
group of closely related viruses. To address this issue
we performed neutralization experiments using three vi-
ruses (2060, 2072, and 1010) belonging to the different
sequence groups defined above with sera of patients
infected by HTLV-I whose gp46 coding sequences were
known. Two tests based on different cellular systems
were used to evaluate the neutralizing potential of the
sera against HTLV-I: syncytia and reporter gene inhibi-
tion assays. In the latter assay, the inhibition (50 to 80%)
observed with the addition of AZT indicated that the
transactivation is partly due to cell fusion and partly to
virus infection (data not shown). To evaluate possible
differences in neutralization patterns of sera, only those
with a strong neutralizing activity on at least one virus
were considered.
Cross-neutralization of 2060 and 2072 HTLV-I isolates
with the corresponding sera
In a first set of experiments, we performed cross-
neutralization of 2060 and 2072 viruses with the corre-
sponding sera. Figure 2A shows the results obtained in
the reporter gene inhibition assays used to titrate neu-
tralizing antibodies. To circumvent the nonspecific cyto-
toxic activity present in some sera at low dilutions, neu-
tralization experiments were performed by starting se-
rum dilutions at 1/300.
At low dilution, the 2060 serum almost completely
neutralized the virus produced by either the 2060 or the
2072 cell line (mean values 94% for both) and only one
dilution difference in titer (ID50) was observed on the
different viruses (Table 1). The neutralization potential of
the 2060 serum did not differ significantly with respect to
the 2060 or 2072 viruses (P 5 0.1). In contrast, the 2072
serum which readily neutralized the autologous virus
(82% at 1:300 dilution) led to only a 50% inhibition of
b-galactosidase induction by the 2060 virus at low dilu-
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tion. The ID50 of the 2072 serum was 2860 on the 2072
virus and only 370 on the 2060 virus. Statistical analysis
confirmed that the 2072 serum neutralized the 2072 virus
more efficiently than it did the 2060 heterologous one
(P , 0.01). These data could not be attributed to differ-
ences in viral production by each cell line since the
neutralization titers of the 2060 and 2072 sera on the
2072 virus were equivalent, the 2072 serum titer being
even slightly higher than that of the 2060 serum.
Similar results were obtained in the syncytia inhibition
assay. The 2060 serum neutralized syncytia induced by
HTLV-I 2060 or 2072-producing cells equally well (P 5
0.57, ns), whereas the 2072 serum prevented syncytia
formation induced by 2072 HTLV-I-infected cells more
efficiently than it did with 2060-producing cells (P ,
0.01). Taken together, these data indicate that in these
two paired HTLV-I viruses and sera, strain-specific neu-
tralizing antibodies were present in one serum (2072
serum), while the antibodies in the 2060 serum recog-
nized the neutralizable epitopes on both viruses equally
well.
Neutralization of 2060, 2072, and 1010 viruses by
different HTLV-I-positive sera
The results of the cross-neutralization experiments
between the 2060 and 2072 viruses suggested that a
cosmopolitan HTLV-I could elicit some strain-specific
neutralizing antibodies. To confirm and extend this find-
ing, the neutralization potentials of 12 HTLV-I-positive
sera listed in Table 1 were assayed on HTLV-I produced
by 2060, 2072, or 1010 cells, each viral strain belonging to
a different group as defined in Fig. 1. For the third group
of viruses, no HTLV-I-producing cell line and correspond-
ing sera both originating from the same patient were
available. We used as an HTLV-I-producing cell line Kar-
pas 1010. This cell harbors several proviruses, one of
which has been partially sequenced by Malik et al.
(1988). The published env sequence contained a stop
codon in the env gene corresponding to aa position 273
and thus belongs to a defective provirus. However, 1010
cells contain at least one provirus with a functional env
gene since these cells induced syncytia in coculture with
susceptible cells and activated b-galactosidase synthe-
sis when cocultivated with BHK21-pA18G.
The neutralizing potential of the sera was evaluated on
the three HTLV-I strains using the reporter gene inhibi-
tion assay and when enough serum was available by
both reporter gene and syncytia inhibition assays. Sera
of four patients infected with HTLV-I belonging to group
I env sequences (2031, 2032, 2085, and 2709) completely
neutralized the 2060 virus (maximum inhibition ranged
from 92 to 99%) with ID50 . 2550 in the reporter gene
FIG. 1. Alignment of amino acid changes observed in the envelope glycoprotein sequences encoded by different HTLV-I proviruses. Only those
positions where changes were observed in at least one of the above sequences are listed. Amino acid sequences were deduced from nucleotide
sequences previously reported in six cases: MT2 (27), ATK (28), pt1 (21), 2315 (29), and HS35 and 1010/3 (24). The other 12 amino acid sequences
were deduced from newly established HTLV-I envelope nucleotide sequences. (*)Corresponds to a stop codon.
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inhibition assay (Table 1). Using the same assay system,
these four sera displayed a strong neutralizing activity
against the 2072 virus (maximum inhibition 92 to 97%)
and the 1010 virus (maximum inhibition 97 to 100%). In all
cases, ID50 values for 2060-, 2072-, or 1010-producing
cells differed by less than one serum dilution. Statistical
analysis indicated that these four sera did not differ in
neutralization activity toward the different viruses: 2060
or 2072 (P 5 0.92 for serum 2031, P 5 0.06 for serum
2032, P 5 0.92 for serum 2085, and P 5 0.14 for serum
2709) and 2060 or 1010 (P 5 0.55 for serum 2085, P 5
0.63 for serum 2031). As expected, the 2060 serum dis-
played an identical neutralization pattern toward the vi-
ruses produced by the 1010 and 2060 cell lines (P 5
0.63). Syncytia inhibition assay by the 2085 serum was
carried out using 2060, 2072, or 1010 cells as inducers. In
all cases, a high level of inhibition was observed (98 to
100%), with ID50 values differing by less than one serum
dilution. Taken together, these results indicate that sera
2031, 2032, 2060, 2085, and 2709 contained high titers of
antibodies neutralizing viruses produced by the 2060,
2072, or 1010 cell lines with equal efficiency.
The analysis of the sera from patients infected with
viruses of the second group, harboring a surface env
protein more closely related to that of the 2072 virus, was
rather limited as we only possessed sufficient amounts
of two sera. Among these sera only one (2056) could be
used for its high titer in reporter gene and syncytia
assays utilizing the 2072 virus (100% maximum inhibition,
ID50 5 1225). The neutralization potential of the 2072 and
2056 sera was analyzed on viruses produced by the 1010
cells (Table 1). In both reporter gene and syncytia inhi-
bition assays, the 2072 serum partially neutralized the
HTLV-I produced by the 1010 cells (maximum inhibition
58 and 37%, respectively, even at low serum dilution).
Statistical analysis showed that the level of neutralization
of the 1010 virus by the 2072 serum was significantly
different from that observed with the 2072 virus (P 5
0.024 in a reporter gene inhibition assay and P , 0.01 in
a syncytia inhibition assay). In contrast, the 2056 serum
displayed equivalent neutralizing activity against the vi-
ruses produced by the three cell lines; the slight differ-
ences observed were not statistically significant (2060
versus 2072, P 5 0.1; 1010 versus 2072 virus, P 5 0.3).
Finally, four sera (2052, 2315, IP084, and IP145) from
patients infected by HTLV-I belonging to group 3 env
sequences were used to neutralize the three HTLV-I
strains in the reporter gene inhibition assay and when a
sufficient amount of serum was available in the syncytia
inhibition assay. The results of the reporter gene inhibi-
tion assays presented in Table 1 showed that all four
sera contained antibodies inhibiting b-galactosidase in-
FIG. 2. (A) Neutralization curves of 2060 and 2072 viruses by 2060 and 2072 sera. Each point corresponds to the mean (6SD) of three to five values
obtained in independent reporter gene inhibition assays. (B) Neutralization curves of 2060, 2072, and 1010 viruses by IP084 and IP145 sera. Each point
corresponds to the mean (6SD) of three to five values obtained in independent reporter gene inhibition assays.
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duction by the 1010 cells (maximum inhibition ranged
from 73 to 98%). Figure 2B illustrates this finding for the
IP084 and IP145 sera. These four sera possessed inhib-
itory activity, albeit to a lesser extent, when 2060 cells
were used as an HTLV-I producer. The maximum inhibi-
tions fell from 82 to 52% for serum 2052, 90 to 66% for
serum 2315, 98 to 68% for serum IP084, and 73 to 53% for
serum IP145. In all cases, apart from serum 2315, which
displayed a low ID50 to both viruses, the ID50 toward the
2060 virus were lower than those toward the 1010 virus.
These differences were in line with the neutralization
patterns (P 5 0.02 for serum 2052, P 5 0.04 for serum
IP084, P 5 0.04 for serum IP145). Syncytia inhibition
assays with IP084 and IP145 sera were performed using
the 1010 or 2060 cells as inducers (Table 1). High levels
of inhibition of 1010 cell-induced syncytia were obtained
with both sera. The IP084 serum inhibited syncytia in-
duced by the 2060 and 1010 cells to the same extent (P 5
0.2), whereas the IP145 serum more efficiently inhibited
syncytia induced by the 1010 cells (P 5 0.01). When these
four sera were assayed in reporter gene assays using
the 2072 cells as HTLV-I-producing cells, a low level of
inhibition was obtained with the 2052 serum (42%) even
at low serum dilution, whereas strong inhibition was
obtained with the IP084 and IP145 sera (90 and 87%,
respectively). For the 2052 serum, the difference ob-
served on the 2072 and 1010 viruses was statistically
significant (P 5 0.02), whereas no significant differences
in neutralization titers toward the 2072 or 1010 virus were
observed with the IP084 and IP145 sera (P 5 0.098 for
IP84, P 5 0.05 for IP145).
Taken together, these results indicated that HTLV-I
harboring env sequences defined as group I env se-
quences elicited neutralizing antibodies that completely
neutralized the HTLV-I with the gp46 amino acid substi-
tutions found in groups 2 and 3, while some HTLV-I with
env sequences of groups 2 and 3 elicited strain-specific
neutralizing antibodies.
CONCLUSION
The nucleotide sequence of HTLV-I proviruses origi-
nating from different regions of the world is highly con-
served. This low level of genetic variation is encountered
in all regions of the viral genome and particularly in the
env gene that encodes for the surface and the trans-
membrane glycoproteins. The majority of HTLV-I-infected
individuals have elevated levels of neutralizing antibod-
ies (Nagy et al., 1983; Clapham et al., 1984; Hoshino et
al., 1985; Minagawa et al., 1992; Astier-Gin et al., 1997)
with cross-neutralizing activity. The exact role of these
neutralizing antibodies during the long asymptomatic
period is unknown, although such antibodies could be a
key host factor in preventing viremia and leading to a
long incubation period. Their role in the prevention of
HTLV-I infection in animal models is well documented
(Kataoka et al., 1990; Sawada et al., 1991; Miyoshi et al.,
1992). Different versions of HTLV-I envelope proteins
TABLE 1
Neutralization of HTLV-I Produced by 2060, 2072, and 1010 Cells by Human Sera
Sera
2060 cells 2072 cells 1010 cells
Reporter gene
assay Syncytia assay
Reporter gene
assay Syncytia assay
Reporter gene
assay Syncytia assay
ID50
Maximum
inhibition
(%) ID50
Maximum
inhibition
(%) ID50
Maximum
inhibition
(%) ID50
Maximum
inhibition
(%) ID50
Maximum
inhibition
(%) ID50
Maximum
inhibition
(%)
2031 6100a 92 10150 100 8700 97 ND ND 7400 97 ND ND
2032 7150 99 ND ND 3766 97 ND ND ND ND ND ND
2060 4630 94 5375 99 1516 94 8700 91 3500 100 1300 96
2085 7000 96 7666 99 5666 97 10300 100 3150 100 4100 98
2709 2550 95 ND ND 3150 92 ND ND ND ND ND ND
2056 515 77 507 58 1225 100 1183 86 1500 81 625 63
2072 370 50 387 60 2860 82 2500 86 390 58 ,300 37
2704 300 50 ND ND 440 63 ND ND ND ND ND ND
2052 300 52 ND ND 250 42 ND ND 775 82 ND ND
2315 600 66 ND ND 800 86 ND ND 680 90 ND ND
IP084 833 68 1700 84 1860 90 1550 94 6100 98 1825 90
IP145 516 53 600 65 1900 87 1050 94 1400 73 2088 78
Note. Neutralization of HTLV-I produced by 2060, 2072, or 1010 cells. ID50 and maximum inhibition values are mean values obtained in three to five
independent experiments, except for 2052 serum on 2072 cells, for which only one value was available.
a ID50 is the reciprocal of the serum dilution giving a 50% reduction in the number of blue cells or in the absorbance at 620 nm of the positive
control (coculture in the absence of human sera) after subtraction of the background values obtained with indicator cells in the absence of
HTLV-I-producing cells.
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obtained by chemical synthesis or genetic engineering
have been shown to protect rats, rabbits, and monkeys
against HTLV-I infection, although the relative roles of
cellular and humoral responses have yet to be deter-
mined (Nakamura et al., 1987; Shida et al., 1987; Ford et
al., 1992; Baba et al., 1995; Hakoda et al., 1995; Kazanji et
al., 1997). These findings indicate that effective protec-
tion against HTLV-I in humans could be obtained with a
suitable vaccine.
The protective humoral and cellular immune response
elicited by vaccine components could be foiled by the
existence of antigenically different forms of HTLV-I pro-
teins. In this respect, an incomplete cross-reactivity be-
tween cosmopolitan and Melanesian strains of HTLV-I
has been observed. But the effects of amino acid
changes in the env sequences, even if rare, on the
neutralizing and cytotoxic activities induced in humans
have not been investigated in detail.
To address this issue, we performed cross-neutraliza-
tion experiments using three HTLV-I strains produced by
lymphoid cell lines (2060, 2072, and 1010) established
from HTLV-I-infected individuals living in the Caribbean
Basin or French Guiana with 12 sera of patients infected
by HTLV-I bearing a gp46 surface envelope glycoprotein
with amino acid changes at several positions. The re-
sults showed that the neutralization pattern of the sera
clearly differed and could be classified in three catego-
ries. The first 5 sera (2031, 2032, 2060, 2085, and 2709)
neutralized the three viruses (2060, 2072, and 1010) with
an equivalent titer, indicating that the neutralization ca-
pacity of their antibodies was not affected by the different
amino acid sequences of the surface envelope gp46. The
neutralization titers were relatively high compared to
those of other sera tested, possibly due to the fact that 4
of these 5 sera came from patients with TSP/HAM or
Sicca syndromes, two HTLV-I-associated pathologies
where the immune response against the virus is stronger
than in asymptomatic carriers or ATL patients. The sec-
ond group of sera, 2056 and 2072, gave a maximum level
of inhibition and a higher ID50 toward the 2072 virus than
toward the 2060 or 1010 viruses. These differences were
statistically significant only with 2072 serum. This was
attributed to the relativity low antibody titer in the 2056
serum compared to 2072 or to differences in gp46 amino
acid sequences at two positions (108 and 173). This
incomplete neutralization of 2060 and 1010 viruses (50
and 58% with ID50 370 and 390, respectively) by the 2072
serum was observed in both syncytia and reporter gene
inhibition assays, indicating that this serum contained
strain-specific antibodies (82% inhibition and ID50 2860
toward 2072 virus). Finally, the 2052, IP084, and IP145
sera had a stronger neutralization potential and a higher
ID50 on the 1010 than on the 2060 virus in the reporter
gene inhibition assay. The 2052 serum also partially
neutralized the virus produced by 2072 cells, whereas
neutralizing antibodies in the IP084 and IP145 sera rec-
ognized the neutralizable epitopes present on both the
1010 or 2072 viruses equally well. These results obtained
in the reporter gene inhibition assay were confirmed in
the syncytia inhibition assay performed with the IP145
but not with the IP084 serum. This latter serum inhibited
the syncytia induced by the three viruses equally well.
This was unexpected, as the gp46 encoding sequences
of the infecting viruses were identical for both IP084 and
IP145 patients. It could have been due to variations in the
gp21 encoding sequence or in other regions of the viral
genome or to differences in the immune response be-
tween the two individuals. Unfortunately, activities in the
two assays from the serum from patient 2704 infected
with an HTLV-I harboring several amino acid changes in
common with the 2072 virus and from that of patient 2315
more closely related to the 1010 virus were not high
enough to provide reliable data.
The experiments reported here did not allow us to
identify the residue(s) involved in the differences ob-
served in neutralization potential of the sera analyzed.
Compared to the 2060 virus, the 2072 virus harbored four
amino acid changes in the gp46 sequence and one in the
gp21 sequence. The 2072 and 1010 viruses differed in
nine amino acids in gp46 and three amino acids in gp21
(Fig. 1). It is noteworthy that the three patterns of neu-
tralization observed fit well with the three groups of
sequences defined in Fig. 1. These groups were essen-
tially based on sequence similarities in the gp46 domain
between aa 187 and 199, which harbor neutralizable
epitopes identified in several laboratories (Hart et al.,
1995). Each group differed by one amino acid change at
either position A187 3 T or P192 3 S. These substitu-
tions affects the recognition of this gp46 domain by
monoclonal (Schulz et al., 1991) and human antibodies
(Edouard et al., 1994). Our results are in accordance with
a possible involvement of amino acids at these two
positions in the antigenicity of neutralizable epitopes.
However, differences observed in neutralization pattern
between the 2056 and 2072 sera, and between 2052 and
IP084 and IP145, point to a role for other residues such
as C1083 Y or I1733 V and P1603 S or S2503 P3
L (Fig. 1) in the binding of neutralizing antibodies on the
envelope protein at the surface of viral particles. Site-
directed mutagenesis could specify the amino acid(s)
involved in the differential recognition by neutralizing
antibodies, which would help identify new epitopes in-
volved in seroneutralization of this virus. Indeed, all
epitopes identified so far have been through the use of
short synthetic peptides that only enable identification of
linear epitopes. Neutralizing monoclonal antibodies spe-
cific for different retroviruses often recognize conforma-
tional epitopes involving amino acids remote from the
primary sequences. A recent report indicated that at
least four conformational epitopes within HTLV-I gp46
are recognized by neutralizing antibodies (Hadlock et al.,
1997).
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Our results throw more light on the sequence(s) of env
proteins that is able to induce a neutralizing antibody
response against a wide range of HTLV-I viruses. Such a
response could perhaps be obtained using a molecule
based on a unique sequence, close to those of our group
1 of viruses, or from a combination of molecules with
different specificities.
MATERIALS AND METHODS
Sera
Human sera used for inhibition of syncytium formation
and b-galactosidase induction in pA18G-BHK21 cells
were provided by: Dr. J. C. Vernant (La Meynard Hospital,
Fort-de-France, Martinique), Dr. J. F. Moreau and Dr.
Sarthou (Institut Pasteur Cayenne, French Guiana), Dr. S.
Sainte-Foie and Dr. C. Hajjar (Centre Hospitalier Inter-
communal de Basse-Terre/Sainte-Claude, Guadeloupe),
and Dr. M. C. Georges-Courbot (CIRMF, Franceville, Ga-
bon). All sera were heated for 30 min at 56°C before use.
The presence of HTLV-I antibodies in these sera was
assessed using a commercially available Western blot
diagnostic kit (Diagnostic Biotechnology 2.3).
HTLV-I-infected cells
The lymphoid cell lines 2060 and 2072 (Nicot et al.,
1993) were maintained in RPMI 1640 supplemented with
10% heat-inactivated fetal calf serum (Whittaker), 100
U/ml penicillin, 100 mg/ml streptomycin, and 200 U/ml
recombinant IL2 (Chiron, France). The lymphoid cell line
1010 (Malik et al., 1988), kindly provided by Dr. A. Karpas
(Cambridge University, UK), was grown in the same me-
dium without IL2.
Inhibition of reporter gene induction by human sera
This quantitative assay is described in detail else-
where (Astier-Gin et al., 1997). Briefly, human sera (serial
log 3 dilutions starting at 1:300) were added at the
initiation of cocultures between pA18G-BHK21 cells car-
rying the LacZ reporter gene under the control of the
HTLV-I LTR (Astier-Gin et al., 1995)- and HTLV-I-produc-
ing cells. All cocultures were maintained for 72 h in the
presence of 12-O-tetradecanoylphorbol-13-acetate (TPA),
and b-galactosidase activity was revealed by in situ
staining with X-gal or by a colorimetric method using
CPRG as enzyme substrate. The serum titer (ID50) was
expressed as the reciprocal of the serum dilution giving
a 50% reduction in the number of blue cells or of the
absorbance at 620 nm of the positive control (coculture
in absence of human serum) after subtraction of back-
ground values obtained with the pA18G-BHK21 cell cul-
ture alone.
Syncytium inhibition assay by human sera
A b-galactosidase assay was employed for quantita-
tive evaluation of syncytium formation (Denesvre et al.,
1995). Human sera at various serial log 3 dilutions (start-
ing at final dilution 1:300) were incubated for 1 h at 37°C
with 7 3 104 HTLV-I-producing cells in 1 ml RPMI 1640
containing 10% heat-inactivated fetal calf serum in wells
of 24-well tissue culture plates (Falcon). One hundred
thousand Cos-HIV-LTR-LacZ and 60000 XC-Tat cells
(kindly provided by Dr. P. Sonigo, Institut Cochin de
Ge´ne´tique Mole´culaire, Paris, France) were then added
and cocultured for 24 h. The b-galactosidase activity
appearing after cell fusion was monitored by the colori-
metric method mentioned above. The serum titer was
expressed as the reciprocal of the serum dilution giving
a 50% reduction in the absorbance at 620 nm of the
positive control (coculture in absence of human serum)
after subtraction of background values obtained in wells
without HTLV-I-infected cells.
DNA sequences
The env gene sequences of HTLV-I proviruses were
determined according to the dideoxy method of Sanger
et al. (1977) on the PCR product amplified from genomic
DNA isolated from peripheral blood lymphocytes of in-
fected patients. Before sequencing, PCR products were
purified using the Wizard PCR preps DNA purification
system (Promega) or subcloned using the TA cloning
system (In Vitrogen). The sequence reaction was per-
formed with the sequenase sequencing Kit (USB) for
manual sequence or for DNA sequencer (LICOR). Gene-
Bank Accession numbers are gbL76050 (2031gp46),
gbL76051 (2032gp46), gbL76055 (2052gp46), gbL76057
(2056gp46), gbL76059 (2060gp46), gbL76061 (2072gp46),
gbL76066 (2085gp46), gbL76042 (2704gp46), gbL76045
(2709gp46), AF029074 (IP084gp46), AF029072 (IP145gp46),
AF029075 (2060gp21), and AF029073 (2072gp21).
Statistical analysis
Each experiment was repeated three to five times.
Results were expressed as means 6 SD. The signifi-
cance of differences observed between neutralization
patterns were determined using paired, two-tailed, Stu-
dent’s t tests for all experiments. Confirmation was ob-
tained by two-way variance analysis (ANOVA) for assays
presented in Fig. 2. Differences were described as sta-
tistically significant when P , .05.
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